India opens doors for import of Moderna, its fourth vaccine

Tribune News Service

New Delhi, June 29

India on Tuesday licensed its fourth Covid-19 vaccine for restricted emergency use with the Drugs Controller General of India (DCGI) approving Cipla’s request for import of US firm Moderna’s jabs.

Editorial: Second wave burden

Moderna will be the first internationally manufactured ready-to-inject shot to enter the Indian market once the import formalities are concluded. India has earlier licensed Covaxin, Covishield (both made in India) and the Russian Sputnik V for restricted emergency use. With the Centre already having waived all requirements for local clinical trials for foreign jabs approved by reputed regulators, Moderna would not need to conduct any bridging studies at home.

Only the first 100 persons who receive the shot would have to be watched for adverse events. Unlike Sputnik V which is being produced in India, Moderna will only be imported although the government is hoping Moderna would consider manufacturing in India.

Member, NITI Aayog, VK Paul said the regulatory approval had opened the pathway for import of Moderna but did not put a timeline to the availability of the shots in the domestic market.

Asked about indemnity from legal costs for foreign developers, including Moderna and Pfizer have sought, Paul said, “That is under consideration and is being addressed.”

Asked when Moderna would enter India, Paul said: “Let’s wait and see how today’s opportunity will be used for importing Moderna into India”.

11-mth Covishield gap ‘improves’ immunity

Oxford University researchers have revealed that an 11-month gap between first and second doses of Covishield leads to better immune response.

US announces $41 mn additional aid to India

The US has announced an additional $41 million aid to help India respond to the pandemic and strengthen preparedness for health emergencies.